Our in vivo results suggest that: (1) ONE can protect mice with HFD against early stage of hepatosteatosis and obesity, (2) ONE can activate FAO in liver via upregulation of SPHK2, and (3) ONE induces expression of trans-differentiated and browning genes in WAT. This evidence concerns the gene SPHK2 and Obesity.